GLOBALT Investments LLC / GA 13F: Cuts ABT Stake by $5.3M
Key Points
- GLOBALT Investments LLC reduced its position in Abbott Laboratories by 53,805 shares, bringing its total down to 7,216 shares valued at approximately $713,157.
- The stock recently traded at $103.13, about equal to its closing price of $103.10 on October 27, 2026, and is 21.9% below its 52-week high of $132.03.
- Abbott Laboratories has a market cap of about $181.5 billion and a P/E ratio of 39.0, with a strong buy consensus from analysts.
Get Abbott Laboratories text alerts
We text you when insiders, Congress, analysts or big funds move on $ABT.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Abbott Laboratories alert may contain errors. Disclosures
In a filing on October 27, 2026, GLOBALT Investments LLC cut its stake in Abbott Laboratories (ABT) by 53,805 shares, reducing its total to 7,216 shares. This reduction represents a decrease of about 88.2% in its holdings, valued at approximately $5.3 million.
ABT
Abbott Laboratories
Where Abbott Laboratories Fits in GLOBALT Investments' Portfolio
GLOBALT's stake in Abbott now accounts for 0.04% of its total reported value of approximately $1.68 billion. The position ranks 43rd out of 212 total holdings in the fund's portfolio.
Other Institutional Activity in Abbott Laboratories
Capital International Investors reduced its holdings in Abbott by 2,842,222 shares, leaving it with 34,654,113 shares valued at about $3.57 billion. This represents a decrease of 7.6%.
Abbott Laboratories Stock Down 0.5%
Abbott's stock recently traded at $103.13, about equal to its closing price of $103.10 on October 27, 2026. The shares are currently 21.9% below their 52-week high of $132.03, but they are above their 52-week low of $81.97 by 25.8%.
Recent Earnings
Abbott Laboratories reported trailing twelve-month revenue of approximately $48.2 billion, with a net margin of 9.7%. The company is scheduled to announce its next earnings on January 28, 2027.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Abbott Laboratories
Recently, several insiders have made notable trades. Director John G. Stratton bought 2,000 shares at an average price of $86.82 on May 7, 2026, totaling $173,640. Officer Louis H. Morrone sold 5,850 shares on August 11, 2026, valued at $642,506. CEO Robert B. Ford sold 398,832 shares on August 25, 2026, totaling about $46.2 million.
Analysts Set New Price Targets
On October 22, 2026, Citigroup maintained its "Buy" rating on Abbott with a price target of $122. RBC Capital also maintained an "Outperform" rating with a target of $125. However, Argus Research downgraded the stock to "Hold" on the same day as GLOBALT's filing.
About Abbott Laboratories
Abbott Laboratories, based in Abbott Park, Illinois, develops and sells health care products worldwide across four segments: pharmaceuticals, diagnostics, nutrition, and medical devices. This cut in stake could signal shifts in investment strategy for GLOBALT as it navigates its portfolio.
Bottom Line
Investors should keep an eye on Abbott's upcoming earnings report on January 28, 2027, and watch for any further changes in institutional holdings following this recent filing. GLOBALT's significant reduction in Abbott shares could indicate a reassessment of its value in the fund's strategy.
Related Filing Alerts
Source: GLOBALT Investments LLC / GA's 13F filing on $ABT (Oct 27, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts